Decoding Neurodegenerative Disease with NULISA: Disease‐Specific Biomarkers and Predictive Signatures Unveiled
Our study is a comprehensive analysis of central nervous system and inflammatory proteins measured in plasma using NULISA in the context of AD. It validates the predictive accuracy of plasma pTau217 and its strong correlation with Centiloid levels and other neuroimaging biomarkers when measured with this novel platform. These findings further establish the potential of NULISA quantification as a reliable tool for research and clinical applications in neurodegenerative diseases.
Authors
- Ciyang Wang (ORCID: https://orcid.org/0000-0001-5253-0490)
- Katherine Gong (ORCID: https://orcid.org/0009-0008-7614-9545)
- Maulikkumar Patel (ORCID: https://orcid.org/0000-0003-3914-2797)
- Menghan Liu (ORCID: https://orcid.org/0009-0008-9902-5983)
- Jigyasha Timsina (ORCID: https://orcid.org/0000-0003-4794-9187)
- Laura Ibanez
- Muhammad Ali
- Suzanne E. Schindler
- John C. Morris
- David M. Holtzman
- Yike Chen
- Tammie L.S. Benzinger
- Gyujin Heo
- Carlos Cruchaga
Institutions
- Washington University in St. Louis (US)
- Hope Center for Neurological Disorders (US)
- Prevent Alzheimer’s Disease 2020 (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70856_101191
- Primary Topic
- Amyotrophic Lateral Sclerosis Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00